Taglich Brothers Lowers Earnings Estimates for Cosmos Health

Cosmos Health Inc. (NASDAQ:COSM) – Stock analysts at Taglich Brothers decreased their Q3 2025 earnings estimates for shares of Cosmos Health in a research report issued to clients and investors on Monday, November 25th. Taglich Brothers analyst H. Halpern now anticipates that the company will earn ($0.01) per share for the quarter, down from their previous estimate of $0.03. The consensus estimate for Cosmos Health’s current full-year earnings is ($0.48) per share. Taglich Brothers also issued estimates for Cosmos Health’s Q4 2025 earnings at $0.04 EPS.

Cosmos Health Price Performance

NASDAQ COSM opened at $0.79 on Wednesday. The company has a current ratio of 1.44, a quick ratio of 1.24 and a debt-to-equity ratio of 0.08. The company has a fifty day simple moving average of $0.79 and a 200 day simple moving average of $0.91. The company has a market cap of $18.33 million, a P/E ratio of -0.32 and a beta of 5.72. Cosmos Health has a 1 year low of $0.47 and a 1 year high of $1.65.

Cosmos Health Company Profile

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names.